Taking place in Boston (August 17–19, 2026), the 5th Oligonucleotide Analytical Development & CMC Summit is a premier event dedicated to advancing analytical and CMC strategies for oligonucleotide therapeutics. Bringing together experts from Alnylam, Biogen, Ionis Pharmaceuticals, Amgen, and Avidity Biosciences, the meeting tackles key challenges in impurity control, complex chemistries, and scalable manufacturing. Attendees will gain insights into cutting-edge analytical tools including mass spectrometry and sequencing, alongside […]

The 6th Annual Oligonucleotides for CNS Summit USA returns to Boston on 19–21 August 2026, uniting 160+ leaders across pharma and biotech to accelerate the discovery, translation and clinical success of CNS‑targeted oligonucleotide therapies. As advances in RNA chemistry, delivery technologies and clinical evidence unlock previously undruggable CNS targets, this meeting is the industry’s most […]

As iPSC therapies transition from promise to clinical reality, the 6th iPSC Drug Development Summit arrives at a pivotal moment for biopharma leaders advancing next-generation cell therapies. Bringing together senior scientists, CMC experts, and decision-makers, this industry-focused meeting is dedicated exclusively to accelerating iPSC-based drug development from discovery through clinical translation and commercialization. This year’s […]

The Neuropsychiatric Drug Development Summit is the definitive meeting for biopharma leaders shaping the future of psychiatric R&D. At a time of renewed momentum in neuropsychiatry, this summit brings together senior decision‑makers to redefine how the industry translates science into successful, patient‑centred therapies. Across discovery, translational science, and clinical development, the agenda showcases the most […]

The First Industry‑Led Meeting Dedicated to Advancing Next‑Generation COPD Therapeutics The COPD Drug Development Summit is the first and only industry‑driven forum designed to accelerate meaningful innovation in chronic obstructive pulmonary disease. With the approval of the first biologic therapy marking a historic turning point, COPD R&D is entering a new era, one defined by […]

All eyes are on the next wave of CAR and TCR innovation. Success is no longer defined by clinical wins alone, but by smarter biological design, delivery strategies and manufacturing breakthroughs to lower COGs, expand patient access and secure commercial viability. With this, the 11th CAR-TCR Summit is making its hotly anticipated return to Boston, […]

The Measuring Patient Engagement Summit Europe is the leading industry forum dedicated to supporting biopharma in quantifying and demonstrating the true impact of patient engagement. As regulatory expectations rise and internal stakeholders demand a clearer return on investment, the need for robust, evidence-based frameworks has never been greater. This three-day summit brings together over 70 […]

4th TRP Supply Chain & Manufacturing Summit (September 15–17, 2026 | Boston, MA) Radiopharmaceuticals are entering a defining stage of development. As clinical programs advance into Phase II, Phase III, and commercial readiness, the ability to manufacture and deliver therapies reliably has become one of the industry's greatest challenges. Rising demand for isotopes, infrastructure constraints, […]

The 5th Lipid Nanoparticles Development Summit Europe returns to Berlin, 23rd – 24th  September 2026, as the leading meeting for advancing LNP-enabled gene therapy delivery. Bringing together experts from BioNTech, AstraZeneca, Johnson & Johnson, Sanofi and AbbVie, the summit covers end-to-end LNP development, from formulation through to analytics, CMC and scalable manufacturing. Attendees will explore solutions to overcome liver tropism, enable extrahepatic delivery and engineer next-generation nanoparticle […]

The FDA has shown its' hand. The Plausible Mechanism Framework and new NGS safety guidance signal one thing clearly: regulators want genome editing therapies to reach patients. Biopharma is also pushing back with a surge of novel genome editing assets deployed in the last 2 years, targeting rare and prevalent diseases with scarce treatment options. […]

10th Anniversary Edition of the IPF Summit - September 29 – October 1, 2026 | Boston, MA For a decade, the IPF Summit has been the go-to, discussion-led forum uniting stakeholders across the pulmonary fibrosis ecosystem. In its 10th anniversary year, the stakes, and the opportunity, have never been higher. Following a wave of positive […]

AI is no longer a future concept in life sciences – it is actively reshaping how work gets done, how decisions are made, and how value is created. Yet most organisations are still navigating how to move from ambition to enterprise-wide execution. The Designing the AI-Enabled Life Sciences Workforce Summit Europe is the only forum built […]

The mRNA Process Development & CMC Summit returns for its 5th Anniversary, bringing together the brightest minds in mRNA development, manufacturing, and CMC strategy. As the field continues to evolve at pace, this milestone edition is your opportunity to connect, learn, and stay ahead of the curve with the leaders shaping the future of mRNA […]

Fueled by surging digital pathology partnerships, improved MRD sensitivity and high-plex single‑cell and multi‑omic profiling to breakthroughs, the precision medicine field is evolving rapidly. Building on this momentum, the 16th World Clinical Biomarkers & Companion Diagnostics Summit returns to Boston this fall, uniting 850+ senior stakeholders in the common goal of advancing timely, accessible and […]

Returning as the largest and definitive ADC congress, the 17th World ADC San Diego is THE one-stop bioconjugate shop, bringing together the global ADC community for an unparalleled amalgamation of case studies, development trends and networking opportunities to forge ADC innovation into differentiated, early-line patient outcomes. With 7 streams of end-to-end ADC content across Discovery […]

Early Access Programmes have evolved into a critical, but increasingly complex, part of drug development and launch strategy. What was once a reactive pathway is now a strategic lever shaping timelines, evidence generation, and patient access across global markets. The 5th Operationalise: Early Access Programmes Summit Europe is built for the teams responsible for turning […]

4th Covalent Drug Discovery & Development Summit (October 20–22, Boston, MA) Covalent drug discovery is entering a defining era. Once constrained by safety and selectivity concerns, advances in chemistry, screening technologies, and translational science are unlocking covalent approaches as a powerful strategy to target previously inaccessible biology. As the field evolves, the challenge is no […]

After a decade of innovation, the TPD field has its first drug approval in the form of Arvinas’ Veppanu. Combined with the recovering market of 2026, this clinical validation will unleash a new wave of innovative approaches and push TPD to a new inflection point. Already, the headwinds are reversing with $15B worth of upfront […]

Cell and gene therapies are advancing into late-stage development and commercialization, where raw materials have become a critical determinant of whether programs succeed or fail. Small inconsistencies that once went unnoticed are now triggering regulatory scrutiny, inflating cost of goods, and causing delays that put timelines and patient access at risk. Following the sunshine to […]

The 14th IMPACCT Real-World Evidence Summit is the only dedicated industry forum uniting leaders across RWE, real-world data, evidence generation, HEOR, and market access to tackle the most pressing challenges in the field. From selecting regulatory-ready datasets to embedding AI and advanced analytics into workflows, this summit focuses on how to consistently translate data into […]

GLP-1s changed the treatment paradigm for obesity reaching new heights of efficacy. Now, as unmet need persists and the field looks beyond efficacy alone, momentum is building behind therapies that can deliver lasting weight management through improved tolerability, muscle preservation, personalised treatment approaches, and more convenient administration. As obesity investment and pipeline activity surge across […]

10th Dermatology Drug Development Summit – Discovering, Developing & Commercializing Next-Generation Inflammatory Skin Disease Therapeutics - November 3-5, 2026 | Boston, MA The 10th Dermatology Drug Development Summit returns in 2026 as the leading premier forum dedicated to advancing the discovery, development, and commercialization of innovative therapies for inflammatory skin disease. Marking a decade of […]

The 9th RNA-Targeted Drug Discovery & Development Summit returns to Boston, MA, on November 10–12, 2026, as the industry's only dedicated meeting focused exclusively on RNA-targeted small molecules, bringing together leading minds from biotech, pharma and academia to advance the next generation of RNA-focused therapeutics. As momentum continues to build across the field, driven by recent clinical progress and […]

The 9th Lab Asset & Facility Management (LAFM) Summit 2026 is the leading industry forum dedicated to helping pharmaceutical and biotech organizations optimize lab operations, asset management, facilities, engineering, and research infrastructure. Taking place in Boston, MA from November 10–12, 2026, the flagship event brings together 190+ senior leaders and decision-makers responsible for creating efficient, […]

South Korea’s cell and gene therapy landscape is highly dynamic, as observed from regulatory approvals, clinical trial progress, and manufacturing activity, from over 150 companies in active drug development. Additionally, with global pharma including Bayer, Novartis and more seeing strategic investments into the CGT space within South Korea, greater opportunities for scientific innovation and technology […]

Driven by South Korea’s government making strategic investments in mRNA platforms and growing collaboration between global pharma and local biotech innovators, the field is experiencing renewed development momentum. This is placing the region as a key hotspot for global mRNA innovation and interest. Uniquely positioned as the industry’s most comprehensive biopharma forum, the 2nd World RNA-Based Therapeutic […]

Hot off the press: The biomarker operations and biospecimen community finally has its own dedicated forum. Introducing the inaugural Biomarker Operations & Biospecimen Management Summit, the industry's first, purpose-built meeting for the heads, VPs and leading stakeholders at pharma and biotech directly responsible for biospecimen and biomarker delivery. View the newly released agenda:  https://ter.li/p9sor70u With […]

As model-informed drug development (MIDD) becomes increasingly central to modern drug development strategy, organizations are under growing pressure to leverage quantitative approaches that accelerate timelines, reduce risk, and improve regulatory and clinical success. The 2nd Model-Informed Drug Development Summit, taking place November 17-19, 2026, in Boston, MA, brings together senior leaders in pharmacometrics, clinical pharmacology, […]

Introducing Europe’s first CNS Biomarker Forum. The Novel CNS Biomarkers Summit Europe is the only European meeting dedicated exclusively to advancing fluid, imaging, and digital biomarkers for CNS drug development. Bringing together biomarker, translational medicine, neuroscience, and clinical development leaders, the summit focuses on accelerating the discovery, validation, and implementation of next-generation biomarkers across neurodegenerative and […]

The 8th CNS Drug Delivery Summit is the leading industry forum dedicated to overcoming the challenges of delivering therapeutics across the blood-brain barrier and into the central nervous system. Bringing together experts from biopharma, biotech, and academia, the summit will explore the latest advances in drug delivery technologies, including nanoparticles, antibody shuttles, gene therapy vectors, […]